Increased thyrotrophin and prolactin secretion induced by domperidone in hypothyroid subjects.
The thyrotrophin (TSH) and prolactin (Prl) releasing effects of domperidone, a recently  developed antidopaminergic drug which does not cross the blood-brain barrier, were investigated in 8 women affected by primary hypothyroidism, and were compared to those elicited by another antidopaminergic drug, sulpiride. Domperidone (4 mg iv) induced a clear-cut and sustained rise in both plasma TSH and Prl, with peak levels occurring 15 and 30 min post-injection, respectively. The increments in plasma Prl after domperidone were significantly higher than those in plasma TSH. The TSH and Prl responses induced by domperidone were almost superimposable to those provoked in the same subjects by sulpiride (100 mg im). In view of the inability of domperidone to penetrate into the central nervous system (CNS), these findings imply a 'peripheral' site(s) of action (i.e. anterior pituitary and/or median eminence) for the effect of antidopaminergic drugs on TSH secretion, and, re-iterate the notion that the same 'peripheral' sites are involved in the Prl-releasing effect of these compounds.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001562:Benzimidazoles / Q000494:pharmacology*; D004294:Domperidone; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000097:blood / Q000503:physiopathology*; D008875:Middle Aged; D010880:Piperidines / Q000494:pharmacology*; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D011954:Receptors, Dopamine / Q000187:drug effects; D013972:Thyrotropin / Q000097:blood / Q000378:metabolism*
D001562:Benzimidazoles; D010880:Piperidines; D011954:Receptors, Dopamine; D004294:Domperidone; D011388:Prolactin; D013972:Thyrotropin